What is the current Price Target for the Kyverna Therapeutics stock?

The average Kyverna Therapeutics target price is $16.83. This is 754.48% higher than the current stock price. The highest price target is 1,169.04%, the lowest is 103.05%. 6 Analysts have issued a price target Kyverna Therapeutics 2026 .

How high will the Kyverna Therapeutics stock rise?

No reliable answer can be given as to how high the Kyverna Therapeutics stock will rise. The performance of stocks, including the Kyverna Therapeutics stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Kyverna Therapeutics stock today?

The performance of Kyverna Therapeutics stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Kyverna Therapeutics stock fall?

The decline in Kyverna Therapeutics stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Kyverna Therapeutics Forecast, price target & analysts

$1.98

0.51% today

NYSE, Apr 04, 10:00 pm CET

ISIN

US5019761049

Symbol

KYTX

Reports

Quarter | Annual

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Kyverna Therapeutics Target price 2025 - Analyst rating & recommendation

Kyverna Therapeutics Classifications & Recommendation:

Buy

83%

Hold

17%

Kyverna Therapeutics Price Target

Target Price	$16.83
Price	$1.97
Potential	754.48% register free of charge
Number of Estimates	6

	6 Analysts have issued a price target Kyverna Therapeutics 2026 . The average Kyverna Therapeutics target price is $16.83. This is 754.48% register free of charge higher than the current stock price. The highest price target is $25.00 1,169.04% register free of charge , the lowest is $4.00 103.05% register free of charge .
	A rating was issued by 6 analysts: 5 Analysts recommend Kyverna Therapeutics to buy, 1 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Kyverna Therapeutics stock has an average upside potential 2026 of 754.48% register free of charge . Most analysts recommend the Kyverna Therapeutics stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually

	Dec '24	2025 Estimates
Earnings Per Share $	-3.33	-4.19
	137.86%	25.83%
P/E		negative

1 Analysts have issued a Kyverna Therapeutics forecast for earnings per share. The average Kyverna Therapeutics EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2024. The highest EPS forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics and future valuations:

2024	$-3.33	137.86%
2025	$-4.19 25.83% Unlock
2026	$-3.62 13.60% Unlock
2027	$-3.23 10.77% Unlock

Current
2025	-0.47 17.54% Unlock
2026	-0.54 14.89% Unlock
2027	-0.61 12.96% Unlock

Kyverna Therapeutics...

Current Kyverna Therapeutics Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
HC Wainwright & Co.	Locked ➜ Locked	Locked	Apr 03 2025
Morgan Stanley	Locked ➜ Locked	Locked	Apr 01 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	Nov 20 2024
Wells Fargo	Locked ➜ Locked	Locked	Nov 15 2024
UBS	Locked ➜ Locked	Locked	Oct 10 2024
HC Wainwright & Co.	Locked ➜ Locked	Locked	Sep 19 2024

Analyst Rating	Date
Locked HC Wainwright & Co.: Locked ➜ Locked	Apr 03 2025
Locked Morgan Stanley: Locked ➜ Locked	Apr 01 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	Nov 20 2024
Locked Wells Fargo: Locked ➜ Locked	Nov 15 2024
Locked UBS: Locked ➜ Locked	Oct 10 2024
Locked HC Wainwright & Co.: Locked ➜ Locked	Sep 19 2024

Discover more stocks with a high price target

Novo Nordisk 83.92%

Coinbase Global, Inc. 83.53%

BioNTech SE - ADR 50.09%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now